Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.

 

Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.

 

Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.

 

CHUL
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

222 entries « 2 of 23 »

Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D'Erasmo L, Arca M, Jones A, Bruckert E, Stroes ES, Bergeron J, Civeira F, Witztum JL, Gaudet D

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.

Journal Article

J Clin Lipidol, 12 (4), pp. 920-927.e4, 2018, ISSN: 1933-2874.

Abstract | Links:

Marchand GB, Carreau AM, Weisnagel SJ, Bergeron J, Labrie F, Lemieux S, Tchernof A

Increased body fat mass explains the positive association between circulating estradiol and insulin resistance in postmenopausal women.

Journal Article

Am J Physiol Endocrinol Metab, 314 (5), pp. E448-E456, 2018, ISSN: 0193-1849.

Abstract | Links:

Drouin-Chartier JP, Tremblay AJ, Bergeron J, Laflamme N, Lamarche B, Couture P

Impact of lipoprotein apheresis with dextran-sulfate adsorption on the expression of genes involved in cardiovascular health in the blood of patients with homozygous familial hypercholesterolemia.

Journal Article

J Clin Apher, 33 (1), pp. 104-107, 2018, ISSN: 0733-2459.

Abstract | Links:

Ruel I, Aljenedil S, Sadri I, de Varennes E, Hegele RA, Couture P, Bergeron J, Wanneh E, Baass A, Dufour R, Gaudet D, Brisson D, Brunham LR, Francis GA, Cermakova L, Brophy JM, Ryomoto A, Mancini GBJ, Genest J

Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.

Journal Article

Clin Chem, 64 (2), pp. 355-362, 2018, ISSN: 0009-9147.

Abstract | Links:

Drouin-Chartier JP, Tremblay AJ, Bergeron J, Lamarche B, Couture P

High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.

Journal Article

Atherosclerosis, 270 , pp. 26-32, 2018, ISSN: 0021-9150.

Abstract | Links:

Maltais A, Almeras N, Lemieux I, Tremblay A, Bergeron J, Poirier P, Despres JP

Trunk muscle quality assessed by computed tomography: Association with adiposity indices and glucose tolerance in men.

Journal Article

Metabolism, 85 , pp. 205-212, 2018, ISSN: 0026-0495.

Abstract | Links:

Desmarais F, Bergeron KF, Lacaille M, Lemieux I, Bergeron J, Biron S, Rassart E, Joanisse DR, Mauriege P, Mounier C

High ApoD protein level in the round ligament fat depot of severely obese women is associated with an improved inflammatory profile.

Journal Article

Endocrine, 61 (2), pp. 248-257, 2018, ISSN: 0969-711X.

Abstract | Links:

Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Belanger A, Bergeron J, Bewick D, Brophy JM, Brunham LR, Couture P, Dufour R, Francis GA, Frohlich J, Gagne C, Gaudet D, Gregoire JC, Gupta M, Hegele RA, Mancini GBJ, McCrindle BW, Pang J, Raggi P, Tu JV, Watts GF, Genest J

Simplified Canadian Definition for Familial Hypercholesterolemia.

Journal Article

Can J Cardiol, 34 (9), pp. 1210-1214, 2018, ISSN: 0828-282X.

Abstract | Links:

Brunham LR, Ruel I, Khoury E, Hegele RA, Couture P, Bergeron J, Baass A, Dufour R, Francis GA, Cermakova L, Mancini GBJ, Brophy JM, Brisson D, Gaudet D, Genest J

Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.

Journal Article

Atherosclerosis, 277 , pp. 419-424, 2018, ISSN: 0021-9150.

Abstract | Links:

Brunham LR, Ruel I, Aljenedil S, Riviere JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta M, Couture P, Pearson GJ, Bergeron J, Francis GA, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J, Goguen J, Gaudet D, Pare G, Romney J, Ransom T, Bernard S, Katz P, Joy TR, Bewick D, Brophy J

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.

Journal Article

Can J Cardiol, 34 (12), pp. 1553-1563, 2018, ISSN: 0828-282X.

Abstract | Links:

222 entries « 2 of 23 »
Signaler des ajouts ou des modifications